ODTX
Odyssey Therapeutics, Inc.
Set alert
19.54 USD -0.29 -1.46%
19.12 Day range 20.20
15.56 52-week range 28.76
- YTD
- +19.00%
- 1 year
- +19.00%
- Open
- 19.77
- Prev close
- 19.83
- Mkt cap
- 939.06M
- Vol
- 166.40K
- Avg vol
- 262.12K
- EPS
- -7.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.12
- High
- 20.20
- Forward P/E
- -4.78
- Beta
- 0.00
- Short ratio
- 11.58
- Inst. own
- 83.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 22.53
- 200-d avg
- 19.92
- 1y target
- 35.75
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 707.36M
- Trailing P/E
- 0.00
- Forward P/E
- -4.78
- PEG ratio
- 0.00
- Price / sales
- 10116.56
- Price / book
- 2.37
- EPS (TTM)
- -7.55
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 99.00K
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 310.58M
- Total debt
- 24.82M
- Return on equity
- 0.00%
- Shares outstanding
- 48.06M
- Short % of float
- 5.24%
- 50-day average
- 22.53
- 200-day average
- 19.92
Analyst view
Consensus: none
Price target (mean) 35.75 +83.0% upside
Now 19.54
- Target (low)
- 29.00
- Target (mean)
- 35.75
- Target (high)
- 44.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.93023.
Financials — quick view
ODTX Revenue — quarterly 0
ODTX Net income — quarterly -52.79M
ODTX EPS — quarterly -1.74
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -1.08 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -1.61 | -1.74 | -0.13 | -8.07% |
| Jun 17, 2026 | Mar 31, 2026 | -1.11 | -6.77 | -5.66 | -508.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2026 | HC Wainwright & Co. | init | — | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 18, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Jun 2, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Jun 2, 2026 | TD Cowen | init | — | Buy |
| Jun 2, 2026 | Wedbush | init | — | Outperform |
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- odysseytx.com
News
- Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
- Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
- Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
- UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27
- Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More
- Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting
- Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42
- Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
- Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages
- Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Your note
Sign in to keep a note on ODTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHU SHELLEY | Director | Purchase | May 10, 2026 | 11,111 |
| DIMENSION CAPITAL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2026 | 0 |
| GLICK GARY D. PH.D. | Chief Executive Officer | Conversion of Exercise of derivative security | May 10, 2026 | 415,973 |
| HAAS JASON | Chief Financial Officer | Purchase | May 7, 2026 | 62,908 |
| LEIDEN JEFFREY M | Director | Conversion of Exercise of derivative security | May 10, 2026 | 0 |
| LI NAN LN | Director | Purchase | May 10, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.78% | 5,179,262 | 107.94M | Jun 29, 2026 |
| SR One Capital Management, LP | 7.90% | 3,794,883 | 79.09M | Jun 29, 2026 |
| TPG GP A, LLC | 7.68% | 3,690,146 | 76.90M | Jun 29, 2026 |
| Lightspeed Management Company, L.L.C. | 7.51% | 3,608,443 | 75.20M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 6.24% | 3,001,198 | 62.54M | Jun 29, 2026 |
| Sanofi | 4.14% | 1,991,918 | 41.51M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.15% | 1,033,434 | 21.54M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.11% | 531,096 | 11.07M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.71% | 339,500 | 7.08M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.60% | 288,662 | 6.02M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.52% | 249,100 | 5.19M | Jul 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.38% | 182,547 | 3.80M | Jun 29, 2026 |